ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Short Communication   
  • J Infect Dis Ther, Vol 9(2)
  • DOI: 10.4172/2332-0877.1000453

Infectious Thoracic Aortic Aneurysm after Intravesical Bacillus Calmette-Guerin Instillation Therapy

Shigeki Koterazawa*, Jun Watanabe, Yuichi Uemura, Masayuki Uegaki, Toshiaki Shirahase and Yoji Taki
Department of Urology, Toyooka Hospital, Toyooka, Japan
*Corresponding Author: Shigeki Koterazawa, Department of Urology, Toyooka Hospital, Toyooka, Japan, Email: ktrazawa0515@gmail.com

Received: 02-Mar-2021 / Accepted Date: 17-Mar-2021 / Published Date: 24-Mar-2021 DOI: 10.4172/2332-0877.1000453

Abstract

Intravesical Bacillus Calmette-Guérin instillation therapy after transurethral resection of bladder tumor is considered as the most effective treatment for prophylaxis against the recurrence of high-risk, non-muscle bladder cancer. However, intravesical Bacillus Calmette-Guérin instillation therapy has some characteristic complications. Here, we report a case of infectious thoracic aortic aneurysm related to prior intravesical Bacillus Calmette-Guérin instillation, which consequently allows the spread into the adjacent lung tissue and secretion in sputum of Mycobacterium bovis.

We report a case of infectious thoracic aortic aneurysm related to prior intravesical BCG instillation, which consequently allow the spread into the adjacent lung tissue and secretion in sputum of M bovis.

Keywords: Bacillus Calmette-Guerin; Infectious thoracic aortic aneurysm; Intravesical instillation; Mycobacterium bovis; Sputum

Abbreviations

BCG: Bacillus Calmette-Guérin; TURBT: Transurethral Resection of Bladder Tumor; CT: Computed Tomography; TEVAR: Thoracic Endovascular Aortic Repair; M.bovis: Mycobacterium bovis

Description

An 80 year old man presented to our hospital because of gross hematuria. Cystoscopy and TURBT revealed carcinoma in situ of the bladder. Three weeks later from the TURBT, he was given 80 mg BCG intravesical instillations every week for eight weeks. Two weeks later from the last treatment, he had suffered from long-lasting fever and poor appetite, and lost 10 kg in three months from the last BCG intravesical instillation. In addition to the lack of definitive evidence of BCG dissemination, because of spontaneous improvement of the symptoms, observation without treatment was adopted at that time. Ten months later from the intravesical instillations, he developed bloody sputum. CT revealed an infiltrative consolidation to his upper lung and M.bovis was detected from his sputum by polymerase chain reaction. Under the diagnosis of pulmonary infection of M.bovis, medical therapy for tuberculosis (Isoniazide, Rifampcin, and Ethambutol) was started. After ten months of medical therapy for tuberculosis, there was no improvement in chest X-ray examination. CT revealed an infectious thoracic aortic aneurysm with air in the vascular wall, and he was diagnosised with tuberculous infectious thoracic aortic aneurysm. He was treated with Thoracic Endovascular Aortic Repair (TEVAR), and antibiotic therapy was continued. There was no recurrence at 24 months after treatment with TEVER.

BCG immunotherapy after TUR is the gold standard treatment for non-muscle-invasive bladder cancer (stage pTa, pT1, pTis) [1]. Owing to the presence of viable mycobacteria, several adverse reactions such as fever, hematuria, and lower urinary tract symptoms have been reported [2]. On the other hand, rare cases of serious complications, such as interstitial pneumonitis, military tuberculosis, hepatitis, sepsis, and infectious aortic aneurysm have been reported [3,4]. Among this ectopic dissemination of BCG, infectious aneurysm is a relatively rare entity. The infectious aortic aneurysm often has a long time of onset from BCG therapy, and the mean time is approximately 25 months [5]. This long latency of Mycobacterium in the aortic wall might make the diagnosis difficult. Lamm recommend that if the fever greater than 38.5 prolongs for more than 24 hours after BCG instillations, initial treatment should be aggressive and utilize isoniazid [3]. Witjes et al. also recommend prompt treatment for persistent fever (>38.5ºC for >48 hours) with two or more antimicrobial agents (Fluoroquinolones, isoniazid, and rifampicin) before the diagnosis of the disseminated BCG infection [6].`

It was reported that the mean growth rate of the aortic aneurysm was 0.12 cm/year [7]. Therefore, several factors such as infection of the aortic wall should be considered in this case of the rapid growth of the aneurysm. Considering the negative blood culture results, the infiltrative consolidation to the lung adjacent to the aneurysm and the detection of M.bovis from the sputum, this case may be an infectious aortic aneurysm caused by the disseminated BCG infection.

In our case, bacteria were disseminated hematogenously and colonized his blood vessel wall during continuous mild fever and anorexia after BCG therapy. Retrospectively, the lack of therapeutic intervention at this latent period might facilitate successive aneurysmal formation and invasion of pathogen to the adjacent lung tissue. Therefore, in addition to the prevention of dissemination, urologists should be aware of the possibility of long-lasting latency of ectopic infection of M.bovis such as the case of aortic wall, for the appropriate therapeutic intervention.

Conclusion

Infectious aneurysm caused by M.bovis is one of the complications, which has difficult diagnosis because of its long latency. Every urologist should be aware of how to manage this rare complication, to prevent epidemiologic consequence.

References

  1. Brausi M, Witjes JA, Lamm D, Persad R, Pslou J, et al. (2011) A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 186: 2158-2167.
  2. Brausi M, Oddens J, Sylvester R, Bono A, Beek C, et al. (2014) Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: Results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 65: 69-76.
  3. Lamm DL, Meijden PM, Morales A, Brosman SA, Catalona WJ, et al. (1992) Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147: 596-600.
  4. Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F (2014) Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: Incidence, risk factors, and outcome in a single institution series and review of the literature. Medicine (Baltimore) 93: 236-254.
  5. Orii K, Honda J, Hirai, Y (2012) Tuberculous abdominal aortic aneurysm after intravesical Bacillus Calmette-Guérin therapy. Jpn J Vasc Surg 21: 803-808.
  6. Witjes JA, Palou J, Soloway M, Akaza M, Colombel M, et al. (2008) Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol 7: 667-674.
  7. Coady MA, Rizzo JA, Hammond GL, Mandapati D, Darr U, et al. (1997) What is the appropriate size criterion for resection of thoracic aortic aneurysms? J Thorac Cardiovasc Surg 113: 476-491.

Citation: Koterazawa S, Watanabe J, Uemura Y, Uegaki M, Shirahase T et al. (2021) Infectious Thoracic Aortic Aneurysm after Intravesical Bacillus Calmette-Guérin Instillation Therapy. J Infect Dis Ther 9:453. DOI: 10.4172/2332-0877.1000453

Copyright: © 2021 Koterazawa S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top